Last $27.93 USD
Change Today +0.29 / 1.05%
Volume 104.1K
EBS On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 8:04 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Daniel J. Abdun-Nabi

Chief Executive Officer, President, Director and Member of Strategic Operations Committee, Emergent BioSolutions, Inc.
AgeTotal Calculated CompensationThis person is connected to 17 board members in 2 different organizations across 1 different industries.

See Board Relationships
59$2,160,851
As of Fiscal Year 2013

Background*

Mr. Daniel J. Abdun-Nabi, also known as Dan, has been President of Emergent BioSolutions, Inc. since May 2007 and has been its Chief Executive Officer since April 01, 2012. Mr. Abdun-Nabi served as the Chief Operating Officer of Emergent BioSolutions, Inc. from May 2007 to April 01, 2012. Mr. Abdun-Nabi served as the Senior Vice President of Legal & Corporate Affairs and General Counsel of Emergent BioSolutions, Inc. from December 2004 to April 2007 and served as its ...

Read Full Background

Corporate Headquarters*

2273 Research Boulevard
Rockville, Maryland 20850

United States

Phone: 301-795-1800
Fax: 301-795-1899

Board Members Memberships*

2009-Present
Chief Executive Officer, President, Director and Member of Strategic Operations Committee
2012-Present
Vice Chairman

Education*

JD
University of San Diego School of Law
BA
University of Massachusetts, Amherst

Other Affiliations*

Annual Compensation*

Salary$589,695
Bonus$459,190
Total Annual Compensation$1,048,885

Stock Options*

Restricted Stock Awards$599,035
All Other Compensation$7,650
Exercised Options4,613
Exercised Options Value$38,288
Exercisable Options159,613
Exercisable Options Value$728,511
Unexercisable Options133,312
Unexercisable Options Value$949,010
Total Value of Options$1,715,808
Total Number of Options297,538

Total Compensation*

Total Annual Cash Compensation$1,056,535
Total Short Term Compensation$1,048,885
Other Long Term Compensation$606,685
Total Calculated Compensation$2,160,851
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $27.93 USD +0.29

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
William S. Marth Chief Executive Officer, President and Director
Albany Molecular Research Inc.
--
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
567.0K GBP
Paul Chaplin MSc, Ph.D.Chief Executive Officer and President
Bavarian Nordic A/S
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.